Navigation Links
Shire Engages Palio
Date:1/22/2008

Palio Named Agency of Record for FOSRENOL(R)

SARATOGA SPRINGS, N.Y., Jan. 22 /PRNewswire-FirstCall/ -- Palio, an inVentiv Health (Nasdaq: VTIV) company, is pleased to announce that Shire Pharmaceuticals (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) has engaged Palio as agency of record to lead the professional advertising and promotion for Shire's FOSRENOL, which is part of Shire's renal business unit.

"We are excited to put our team's experience and insight to work on behalf of this important product. And, we look forward to becoming a true marketing partner with Shire's FOSRENOL team," said Mike Myers, president of Palio.

Shire is a global specialty biopharmaceutical company with US operations headquartered in Chester County, Pennsylvania, just outside of Philadelphia.

"Palio's initial concept work on FOSRENOL demonstrated a level of strategic thinking and creativity that was unmatched. Their focus on the brand, their medical insight, and their commitment to our business has raised our expectations," said Joe Schlitz, vice president, US commercial lead, renal business unit, Shire Pharmaceuticals. "At Shire, our mission is to develop and market medicines that improve the quality of life for patients and their caregivers. We're looking forward to working with Palio in achieving our vision."

Palio, a full-spectrum advertising and communications agency headquartered in Saratoga Springs, NY, excels in brand creation that changes the way people think with execution that will Never be forgotten(SM). For more information on Palio, visit http://www.palio.com.

About SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutic
'/>"/>

SOURCE Palio
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...early peek at what would turn out to be a major ne...the ceiling. , ,As a physics post-doc at the Unive...olds sawed a hole in the ceiling of an office of t...ting a specially built spectrometer through the ro...ear view of a faint glowing gas that permeates the...
...., a provider of information management systems, ...portfolio management and investment accounting sol...rder processing through trade execution, accountin... reporting. , ,Brookfield-based Fiserv designed e...sing dates and the software is capable of managing...
...ice-fishing net, a polymer sorting machine and a B...of a field of 22 inventions University of Wisconsi...Days , Feb. 12 and 13. , ,The projects competed fo...ototype Prize, both sponsored by UW-Madison alumni...e marketplace. , ,We place quite a bit of weight o...
...2004 Conference kicked off today with a high leve... who traveled to Scottsdale for this event which i... new consumer and enterprise technology products. ... international media, venture capitalists, and vet...reneurs introduce new products, and technologies i...
Other Biology Technology:Journey Leads Astronomer to New Galactic Structure 2Journey Leads Astronomer to New Galactic Structure 3UW-Madison Undergrads Shine at Innovation Days 2Entrepreneurs Preview Liberating Technologies 2Entrepreneurs Preview Liberating Technologies 3
(Date:7/24/2008)...sity College of Medicine, Hershey, Pennsylvania ha...inically important immune response modifier with p...nt on the Opioid Growth Factor (OGF)-OGF receptor ...ted in the August 08 issue of Experimental Biolog...ly used drug that may lead to development of new a...
(Date:7/24/2008)... might tell potential suitors, "I like the way you...r look. But worms send their valentines via signal...earchers are now cracking, according to a study pu... . , Scientists from the University of Florida,...echnology and the U.S. Department of Agriculture h...
(Date:7/24/2008)... storage in western U.S. forests , Active fire ...caused a widespread increase in fire-intolerant tr...ng on trees within western U.S. forests. These fac...to account for much of North America,s carbon sink...s, Fellows and Goulden compare California forest i...
(Date:7/23/2008)...ternationally renowned scientists from 12 countrie...alia and India to address ancient microscopic fos...ing together the world,s best scientists in the fi...liam Schopf, founder and director of the UCLA Inst...for the Study of Evolution and the Origin of Life ...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 1DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 2Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 1Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 2French paradox redux 3F US vs French on being full 12046 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 2
...ome of patients with type 2 diabetes (DT2) has bee...e of new DNA chip technologies allowing 400,000 DN...s conferring a predisposition to DT2 have been ide...reatic insulin-secreting cells (ZnT8), which is a ...French population was carried out as a French-Brit...
... findings, which are being published the week of F... of the National Academy of Sciences, offer signif...ell as those that lead to abnormal amyloid fibril ...very of novel therapeutic targets for neurodegener... amyloids can play beneficial roles. The subject o...
...ype of protein discovered by Queen’s University re...or antibiotic-resistant bacteria, such as those th... the structure and activity of the protein ?called...rom the departments of Biochemistry and Microbiolo...r new drug development. , “Our group is the fi...
...hers from the Virginia Commonwealth University Mas...arch at the American Association of Cancer Researc...ew combination treatment for chronic lymphocytic l...ant, M.D., Massey,s associate director of translat...d romidepsin (Gloucester Pharmaceuticals) and bort...
Other Biology News:Elucidation of the genome for diabetics with DNA chips 2Elucidation of the genome for diabetics with DNA chips 3Scripps research study reveals structural dynamics of single prion molecules 2Scripps research study reveals structural dynamics of single prion molecules 3Protein discovery targets antibiotic-resistant bacteria 2
Proteinase K Buffer 3.9 ml
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454
Glutathione Agarose Beads 10 ml
Biology Products: